Advertising

The Seattle Times Company

NWjobs | NWautos | NWhomes | NWsource | Free Classifieds | seattletimes.com

Business / Technology


Our network sites seattletimes.com | Advanced

Originally published Friday, October 31, 2008 at 12:00 AM

Comments (0)     Print

MediQuest product approval rejected by FDA

MediQuest Therapeutics said Friday that the U.S. Food and Drug Administration turned down its application to launch a treatment to treat Raynaud's Disease.

Seattle Times business reporter

MediQuest Therapeutics said Friday that the U.S. Food and Drug Administration turned down its application to launch a treatment to treat Raynaud's Disease.

The Bothell-based company said it received an FDA letter saying that the treatment "could not be approved in its present form." The agency identified issues that need to be addressed by the company, but such issues were not disclosed. The company said it will provide an update "when appropriate." The news was first reported by the website Xconomy.

MediQuest had requested expedited approval for what would have been the first product marketed for Raynaud's disease, an ailment that constricts blood flow to the extremities.

Mediquest has 25 employees and has raised some $33 million from investors since 2006.

Ángel González: 206-515-5644 or agonzalez@seattletimes.com

Copyright © 2008 The Seattle Times Company

More Business & Technology headlines...

Print      Share:    Digg     Newsvine

Comments
No comments have been posted to this article.

advertising

UPDATE - 09:46 AM
Exxon Mobil wins ruling in Alaska oil spill case

UPDATE - 09:32 AM
Bank stocks push indexes higher; oil prices dip

UPDATE - 08:04 AM
Ford CEO Mulally gets $56.5M in stock award

UPDATE - 07:54 AM
Underwater mortgages rise as home prices fall

NEW - 09:43 AM
Warner Bros. to offer movie rentals on Facebook

Advertising

Video

Marketplace

 
Most read
Most commented
Most e-mailed
 
 

Most viewed imagesMore

Advertising